183 related articles for article (PubMed ID: 31442391)
1. Does Ivabradine Decrease Cardiovascular Deaths in Heart Failure Patients?
Marciniak TA; Atar D; Serebruany V
Am J Med; 2020 Mar; 133(3):347-351. PubMed ID: 31442391
[TBL] [Abstract][Full Text] [Related]
2. Limited role and benefit of ivabradine in the treatment of angina and heart failure with reduced ejection fraction.
Ennezat PV; Cosgrove S; Marechaux S; Bouvaist H; Le Jemtel TH; Vital Durand D
Acta Cardiol; 2017 Dec; 72(6):664-668. PubMed ID: 28656798
[TBL] [Abstract][Full Text] [Related]
3. Novel drugs for heart rate control in heart failure.
Bielecka-Dabrowa A; von Haehling S; Rysz J; Banach M
Heart Fail Rev; 2018 Jul; 23(4):517-525. PubMed ID: 29594814
[TBL] [Abstract][Full Text] [Related]
4. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT.
Böhm M; Lloyd SM; Ford I; Borer JS; Ewen S; Laufs U; Mahfoud F; Lopez-Sendon J; Ponikowski P; Tavazzi L; Swedberg K; Komajda M
Eur J Heart Fail; 2016 Jun; 18(6):672-83. PubMed ID: 26952245
[TBL] [Abstract][Full Text] [Related]
5. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
Lancet; 2010 Sep; 376(9744):875-85. PubMed ID: 20801500
[TBL] [Abstract][Full Text] [Related]
6. Ivabradine Improves Cardiac Function and Increases Exercise Capacity in Patients with Chronic Heart Failure.
Pei H; Miao W; Xie WZ; Wang W; Zhao D; Su GH; Zhao Z
Int Heart J; 2019 Jul; 60(4):899-909. PubMed ID: 31308326
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy and safety analysis of ivabradine hydrochloride treatment of Chinese patients with chronic heart failure: subgroup analysis of Chinese patients in the SHIFT study].
Hu DY; Huang DJ; Yuan ZY; Zhao RP; Yan XW; Wang MH;
Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Mar; 45(3):190-197. PubMed ID: 28316174
[No Abstract] [Full Text] [Related]
8. Efficacy Profile of Ivabradine in Patients with Heart Failure plus Angina Pectoris.
Borer JS; Swedberg K; Komajda M; Ford I; Tavazzi L; Böhm M; Depre C; Wu Y; Maya J; Dominjon F
Cardiology; 2017; 136(2):138-144. PubMed ID: 27614723
[TBL] [Abstract][Full Text] [Related]
9. Ivabradine: a new frontier in the treatment of stable coronary artery disease and chronic heart failure.
Gammone MA; Riccioni G; D'Orazio N
Clin Ter; 2020; 171(5):e449-e453. PubMed ID: 32901791
[TBL] [Abstract][Full Text] [Related]
10. [From results of BEAUTIFUL trial to results of SHIFT trial: BEAUTIFUL possibility to make a SHIFT in current guidelines].
Lopatin IuM
Kardiologiia; 2011; 51(5):85-90. PubMed ID: 21649600
[TBL] [Abstract][Full Text] [Related]
11. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
Böhm M; Swedberg K; Komajda M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
Lancet; 2010 Sep; 376(9744):886-94. PubMed ID: 20801495
[TBL] [Abstract][Full Text] [Related]
12. Ivabradine for heart failure: regulatory differences in Europe and United States.
Marciniak TA; Hall TS; Atar D; Agewall S; Serebruany VL
Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):119-121. PubMed ID: 30715322
[No Abstract] [Full Text] [Related]
13. Ivabradine: Heart Failure and Beyond.
Chaudhary R; Garg J; Krishnamoorthy P; Shah N; Lanier G; Martinez MW; Freudenberger R
J Cardiovasc Pharmacol Ther; 2016 Jul; 21(4):335-43. PubMed ID: 26721645
[TBL] [Abstract][Full Text] [Related]
14. Effect of ivabradine on major adverse cardiovascular events and mortality in critically ill patients: a systematic review and meta-analyses of randomised controlled trials with trial sequential analyses.
Chen A; Elia N; Dunaiceva J; Rudiger A; Walder B; Bollen Pinto B
Br J Anaesth; 2020 Jun; 124(6):726-738. PubMed ID: 32147100
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of Ivabradine and the Effect on Chronic Heart Failure.
Zhou Y; Wang J; Meng Z; Zhou S; Peng J; Chen S; Wang Q; Sun K
Curr Top Med Chem; 2019; 19(21):1878-1901. PubMed ID: 31400267
[TBL] [Abstract][Full Text] [Related]
16. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
[TBL] [Abstract][Full Text] [Related]
17. Optimal Heart Rate Modulation Using Ivabradine.
Imamura T; Kinugawa K
Int Heart J; 2021 Jul; 62(4):717-721. PubMed ID: 34276025
[TBL] [Abstract][Full Text] [Related]
18. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.
Canet E; Lerebours G; Vilaine JP
Ann N Y Acad Sci; 2011 Mar; 1222():90-9. PubMed ID: 21434947
[TBL] [Abstract][Full Text] [Related]
19. Ivabradine for the Treatment of Acute Mitral-Regurgitation-Related Decompensated Heart Failure.
Lee WC; Fang HY
Cardiology; 2019; 144(3-4):97-100. PubMed ID: 31533098
[TBL] [Abstract][Full Text] [Related]
20. Prognosis of heart failure treated with digoxin or with ivabradine: A cohort study in the community.
Guzman M; Gomez R; Romero SP; Aranda R; Andrey JL; Pedrosa MJ; Egido J; Gomez F
Int J Clin Pract; 2018 Nov; 72(11):e13217. PubMed ID: 30248211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
